NASDAQ · Financial Statements

Radiopharm Theranostics Limited (RADX) Financial Statements

$1.00 NASDAQ: RADX Market Cap $1.29M

Radiopharm Theranostics Limited most recently reported annual revenue of $3.0M, a net loss of $54.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Radiopharm Theranostics Limited: net profit was positive in 0 of 5 reported years; operating margin moved from -225527.7% to -2468.6%, a shift of +223059.1 percentage points; the most recent year shows a net loss of $54.0M.

Income Statement — 5 Years (USD millions)

Metric20212022202320242025
Revenue$0$0$0$4.0M$3.0M
Operating Expenses$20.0M$35.0M$37.0M$42.0M$70.0M
Operating Profit$-20.0M$-35.0M$-37.0M$-38.0M$-67.0M
Operating Margin-225527.7%-11803.3%-12238.4%-1050.6%-2468.6%
Other Income$-10.0M$0$-11.0M$0$11.0M
Interest$9.0M$0$1.0M$0$0
Depreciation$3.0M$3.0M$3.0M$3.0M$3.0M
Profit Before Tax$-30.0M$-35.0M$-48.0M$-38.0M$-56.0M
Tax$-150,000$-110,000$-200,000$-270,000$100,000
Net Profit$-30.0M$-35.0M$-48.0M$-38.0M$-54.0M
EPS$-29.76$-33.00$-36.00$-5.28$-4.56
Dividend Payout0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 2 Quarters (USD millions)

MetricDec '25Jun '26
Revenue$1.0M$1.0M
Operating Expenses$32.0M$41.0M
Operating Profit$-31.0M$-40.0M
Operating Margin-2245.0%-2847.2%
Interest$0$0
Profit Before Tax$-32.0M$-29.0M
Tax$13.5M$660,000
Net Profit$-26.0M$-29.0M
EPS$-675.00$-729.00

Over the 5 years reported for Radiopharm Theranostics Limited, cash stood at $4.0M in the latest year, shareholders' equity was $210.0M, current assets covered current liabilities 1.16 times.

Balance Sheet — 5 Years (USD millions)

Metric20212022202320242025
Total Assets$83.0M$75.0M$72.0M$86.0M$60.0M
Current Assets$27.0M$16.0M$23.0M$40.0M$22.0M
Cash$27.0M$12.0M$19.0M$29.0M$4.0M
Inventory$0$0$0$0$0
Receivables$0$4.0M$1.0M$10.0M$17.0M
Fixed Assets$0$0$0$0$0
Capital Work in Progress$0$0$0$0$0
Investments$0$0$0$0$0
Other Assets$0$0$0$0$0
Total Liabilities$20.0M$29.0M$45.0M$44.0M$38.0M
Current Liabilities$8.0M$13.0M$18.0M$15.0M$19.0M
Borrowings$0$0$0$0$0
Other Liabilities$20.0M$29.0M$45.0M$44.0M$38.0M
Equity$87.0M$97.0M$101.0M$177.0M$210.0M
Reserves$63.0M$44.0M$28.0M$45.0M$25.0M

For Radiopharm Theranostics Limited, operating cash flow was positive in 0 of 5 reported years; free cash flow in the latest year was $0; free cash flow was positive in 0 of 5 years.

Cash Flow Statement — 5 Years (USD millions)

Metric20212022202320242025
Operating Cash Flow$-10.0M$-23.0M$-23.0M$-37.0M$-52.0M
Investing Cash Flow$-57.0M$-3.0M$0$2.0M$46.0M
Financing Cash Flow$-5.0M$-1.0M$-2.0M$-7.0M$0
Net Cash Flow$27.0M$-15.0M$7.0M$11.0M$-23.0M
Free Cash Flow$-38.0M$-25.0M$-23.0M$-37.0M$0

Radiopharm Theranostics Limited (RADX) financials — frequently asked questions

What is Radiopharm Theranostics Limited's annual revenue?

Radiopharm Theranostics Limited (RADX) reported annual revenue of $3.0M in its most recent fiscal year.

What is Radiopharm Theranostics Limited's net profit?

Radiopharm Theranostics Limited (RADX) reported a net loss of $54.0M in its most recent fiscal year.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
RADX Overview RADX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.